Third, while our exclusion criteria aimed to exclude patients who were prescribed SGLT2 inhibitors for heart failure or chronic kidney disease but did not have type 2 diabetes, they entailed that the likely small subset of patients who have a history of heart failure or chronic kidney disease and are prescribed dapagliflozin or empagliflozin as their first treatment for type 2 diabetes were not included in the study; this could marginally influence the generalizability of our findings. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.